search
Back to results

Clinical Efficacy of Left Bundle Branch Area Pacing for Patients With Permanent Atrial Fibrillation and Heart Failure (LBBAP-AFHF)

Primary Purpose

Left Bundle Branch Area Pacing, Biventricular Pacing, Heart Failure

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Left bundle branch area pacing
Biventricular pacing
Sponsored by
Fu Wai Hospital, Beijing, China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Left Bundle Branch Area Pacing focused on measuring Left Bundle Branch Area Pacing, Permanent Atrial Fibrillation, Heart Failure, Biventricular Pacing

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patients aged more than 18 years old
  • Patients diagnosed with heart failure (LVEF<50%) and have received optimal medical therapy for at least 3 months
  • Patients with permanent atrial fibrillation (QRS duration <130ms) which need ventricular pacing, including:

    1. LVEF<50%, NYHA II-IV, drug-refractory atrial fibrillation with the fast ventricular rate, planned atrioventricular nodal ablation due to 1). anticipated low success rate of atrial fibrillation catheter ablation or 2). patients refused to receive catheter ablation or 3). refused to receive another catheter ablation after a previous history of failed procedures
    2. LVEF<50%, NYHA II-IV, atrial fibrillation with slow ventricular rate, anticipated ventricular pacing burden ≥ 40%
  • Written informed consent was provided

Exclusion Criteria:

  • expected survival time is less than 12 months
  • Prior history of mechanical tricuspid valve replacement and/or congenital heart disease (including dextrocardia, transposition of the great arteries, single left persistent left superior vena cava, etc.)
  • Plan for PCI or CABG due to unstable angina or myocardial infarction in 3 months
  • Surgery is required within 1 year due to severe structural heart disease
  • Pregnancy, planned pregnancy or heart transplant
  • Prior history of HCM and/or ventricular septal defect repair, who are unlikely to achieve successful LBBAP procedure.
  • Failure of lead placement due to abnormal anatomy of the coronary sinus or enlarged right atrium, which makes it unable to switch from one pacing modality to another

Sites / Locations

  • Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical SciencesRecruiting
  • Peking University First Hospital
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
  • The Second Hospital of Hebei Medical University
  • The first affiliated hospital of Nanjing medical university

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

LBBAP group

BiVP group

Arm Description

Device: Left bundle branch area pacing(LBBAP) LBBAP is a novel physiological pacing form for ventricular pacing. In patients who received LBBAP, the pacing lead will be placed at the left bundle branch area to achieve a narrow-paced QRS duration.

Device: Biventricular pacing (BiVP) Biventricular pacing is the traditional pacing modality for patients with heart failure. For BiVP, one pacing lead was placed in the coronary sinus, named LV lead, and another lead was placed in the right ventricule.

Outcomes

Primary Outcome Measures

ΔLVEF between baseline and six months post-discharge
ΔLVEF:change in LVEF between baseline and six months after procedure

Secondary Outcome Measures

The immediate success rate of the LBBAP procedure
Successful LBBAP procedure is identified according to ECG and intracardiac ECG electrogram (IEGM) during the procedure. All LBBAP procedures will be categorized as selective left bundle branch pacing (S-LBBP), non-selective left bundle branch pacing(NS-LBBP), or left ventricular septal pacing (LVSP).
The rate of procedure and Device related complications
Procedure complications include pneumothorax, hemothorax, and air embolism. Device related complications include lead and pocket complications
ΔLVEDD between baseline and six months post-discharge
ΔLVEDD:change in LVEDD between baseline and six months after procedure between two groups
ΔLVEDV between baseline and six months post-discharge
ΔLVEDV:change in LVEDV between baseline and six months after procedure between two groups
The echocardiographic response rate of LVEF increase ≥5%
the percentage of patients with change of LVEF ≥5% at 6 month from baseline
The changes of NT-proBNP betwen baseline and 6 months post-discharge
The changes of NT-proBNP betwen baseline and 6 months post-discharge
Composite incidence rate of all-cause mortality and/or hospitalization for heart failure
All-cause death: including cardiovascular and non-cardiovascular deaths. Hospitalization for heart failure: an unplanned outpatient or emergency department visit or inpatient hospitalization in which the patient presented with signs and symptoms consistent with heart failure and required medication therapy.
The echocardiographic response rate of LVEF increase ≥15%
an increase in LVESV ≥15% during follow-up at 6 month compared with baseline
The rate of ΔLVESV ≥15% between baseline and six months post-discharge
the percentage of patients with change of ΔLVESV ≥15% at 6 month from baseline

Full Information

First Posted
September 15, 2022
Last Updated
October 20, 2022
Sponsor
Fu Wai Hospital, Beijing, China
Collaborators
The Second Hospital of Hebei Medical University, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Peking University First Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05549544
Brief Title
Clinical Efficacy of Left Bundle Branch Area Pacing for Patients With Permanent Atrial Fibrillation and Heart Failure
Acronym
LBBAP-AFHF
Official Title
Clinical Efficacy of Left Bundle Branch Area Pacing for Patients With Permanent Atrial Fibrillation and Heart Failure :A Multi-center Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 18, 2022 (Actual)
Primary Completion Date
November 2023 (Anticipated)
Study Completion Date
November 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fu Wai Hospital, Beijing, China
Collaborators
The Second Hospital of Hebei Medical University, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Peking University First Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a multicenter, randomized controlled study. This study aims to compare the clinical efficacy of LBBAP with traditional biventricular pacing in patients with permanent atrial fibrillation and heart Failure
Detailed Description
LBBAP-AFHF is a prospective, multicenter, randomized controlled trial that is designed to determine whether left bundle branch area pacing (LBBAP) may show superiority of improved LV function as compared with traditional biventricular pacing (BiVP) in patients with permanent atrial fibrillation and heart failure (LVEF<50%) who receive atrioventricular nodal ablation due to fast ventricular rate or require high percentage of ventricular pacing due to slow ventricular rate. The primary endpoint of this trial is the change in the LVEF at 6 months after device implantation from baseline. A CRT-P/D device would be implanted and LBBAP lead would be connected to the RA port and LV lead to the LV port. Patients who receive successful LBBAP and BiVP simultaneously during the procedure would be 1:1 randomized to LBBAP or BiVP group after the procedure by device programming. Patients will be followed at 3 and 6 months post-discharge for LVEF and other echographic parameters (including LVESV, response rate), and rehospitalization for heart failure or all-cause death.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Left Bundle Branch Area Pacing, Biventricular Pacing, Heart Failure, Permanent Atrial Fibrillation
Keywords
Left Bundle Branch Area Pacing, Permanent Atrial Fibrillation, Heart Failure, Biventricular Pacing

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
LBBAP group
Arm Type
Experimental
Arm Description
Device: Left bundle branch area pacing(LBBAP) LBBAP is a novel physiological pacing form for ventricular pacing. In patients who received LBBAP, the pacing lead will be placed at the left bundle branch area to achieve a narrow-paced QRS duration.
Arm Title
BiVP group
Arm Type
Active Comparator
Arm Description
Device: Biventricular pacing (BiVP) Biventricular pacing is the traditional pacing modality for patients with heart failure. For BiVP, one pacing lead was placed in the coronary sinus, named LV lead, and another lead was placed in the right ventricule.
Intervention Type
Device
Intervention Name(s)
Left bundle branch area pacing
Intervention Description
Left bundle branch area pacing is a novel physiological pacing modality and is reported to be feasible and safe in patients with heart failure and left bundle branch block.
Intervention Type
Device
Intervention Name(s)
Biventricular pacing
Intervention Description
Biventricular pacing is a widely-established modality to treat heart failure in patients with heart failure
Primary Outcome Measure Information:
Title
ΔLVEF between baseline and six months post-discharge
Description
ΔLVEF:change in LVEF between baseline and six months after procedure
Time Frame
Six months after device implantation
Secondary Outcome Measure Information:
Title
The immediate success rate of the LBBAP procedure
Description
Successful LBBAP procedure is identified according to ECG and intracardiac ECG electrogram (IEGM) during the procedure. All LBBAP procedures will be categorized as selective left bundle branch pacing (S-LBBP), non-selective left bundle branch pacing(NS-LBBP), or left ventricular septal pacing (LVSP).
Time Frame
1 weeks
Title
The rate of procedure and Device related complications
Description
Procedure complications include pneumothorax, hemothorax, and air embolism. Device related complications include lead and pocket complications
Time Frame
6 months
Title
ΔLVEDD between baseline and six months post-discharge
Description
ΔLVEDD:change in LVEDD between baseline and six months after procedure between two groups
Time Frame
6 months
Title
ΔLVEDV between baseline and six months post-discharge
Description
ΔLVEDV:change in LVEDV between baseline and six months after procedure between two groups
Time Frame
6 months
Title
The echocardiographic response rate of LVEF increase ≥5%
Description
the percentage of patients with change of LVEF ≥5% at 6 month from baseline
Time Frame
6 months
Title
The changes of NT-proBNP betwen baseline and 6 months post-discharge
Description
The changes of NT-proBNP betwen baseline and 6 months post-discharge
Time Frame
6 months
Title
Composite incidence rate of all-cause mortality and/or hospitalization for heart failure
Description
All-cause death: including cardiovascular and non-cardiovascular deaths. Hospitalization for heart failure: an unplanned outpatient or emergency department visit or inpatient hospitalization in which the patient presented with signs and symptoms consistent with heart failure and required medication therapy.
Time Frame
6 months
Title
The echocardiographic response rate of LVEF increase ≥15%
Description
an increase in LVESV ≥15% during follow-up at 6 month compared with baseline
Time Frame
6 months
Title
The rate of ΔLVESV ≥15% between baseline and six months post-discharge
Description
the percentage of patients with change of ΔLVESV ≥15% at 6 month from baseline
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients aged more than 18 years old Patients diagnosed with heart failure (LVEF<50%) and have received optimal medical therapy for at least 3 months Patients with permanent atrial fibrillation (QRS duration <130ms) which need ventricular pacing, including: LVEF<50%, NYHA II-IV, drug-refractory atrial fibrillation with the fast ventricular rate, planned atrioventricular nodal ablation due to 1). anticipated low success rate of atrial fibrillation catheter ablation or 2). patients refused to receive catheter ablation or 3). refused to receive another catheter ablation after a previous history of failed procedures LVEF<50%, NYHA II-IV, atrial fibrillation with slow ventricular rate, anticipated ventricular pacing burden ≥ 40% Written informed consent was provided Exclusion Criteria: expected survival time is less than 12 months Prior history of mechanical tricuspid valve replacement and/or congenital heart disease (including dextrocardia, transposition of the great arteries, single left persistent left superior vena cava, etc.) Plan for PCI or CABG due to unstable angina or myocardial infarction in 3 months Surgery is required within 1 year due to severe structural heart disease Pregnancy, planned pregnancy or heart transplant Prior history of HCM and/or ventricular septal defect repair, who are unlikely to achieve successful LBBAP procedure. Failure of lead placement due to abnormal anatomy of the coronary sinus or enlarged right atrium, which makes it unable to switch from one pacing modality to another
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Haojie Zhu, M.D
Phone
+8613167310573
Email
13167310573@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Xiaofei Li, M.D
Phone
+8617801013995
Email
lixiaofei0103@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xiaohan Fan, PhD
Organizational Affiliation
Chinese Academy of Medical Sciences, Fuwai Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100037
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Haojie Zhu
Phone
+8613167310573
Email
13167310573@163.com
First Name & Middle Initial & Last Name & Degree
Xiaofei Li
Phone
+8617801013995
Email
lixiaofei0103@163.com
First Name & Middle Initial & Last Name & Degree
Xiaohan Fan
Facility Name
Peking University First Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100037
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jing Zhou
Facility Name
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
City
Guangzhou
State/Province
Guangdong
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yangxin Chen
Facility Name
The Second Hospital of Hebei Medical University
City
Shijiazhuang
State/Province
Hebei
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ruiqin Xie
Email
ruiqin_xie@sina.com
Facility Name
The first affiliated hospital of Nanjing medical university
City
Nanjing
State/Province
Jiangsu
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jiangang Zou

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Clinical Efficacy of Left Bundle Branch Area Pacing for Patients With Permanent Atrial Fibrillation and Heart Failure

We'll reach out to this number within 24 hrs